Dapagliflozin in Patients with Chronic Kidney Disease

The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.

Dapagliflozin in Patients with Chronic Kidney Disease - PubMed

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained ...

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without ...

The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial (NCT03036150) demonstrated that ...

The long-term effects of dapagliflozin in chronic kidney disease

The DECLARE-TIMI 58 and DAPA-CKD trials demonstrated substantial benefits to patients with CKD through treatment with dapagliflozin, including ...

Dapagliflozin in Patients with Chronic Kidney Disease

We designed the Dapagliflozin and Pre- vention of Adverse Outcomes in Chronic Kidney. Disease (DAPA-CKD) trial to assess the long- term efficacy ...

Dapagliflozin And Prevention of Adverse outcomes in Chronic ...

The results of this trial indicate that dapagliflozin results in salutary effects on renal function among patients with CKD, with or without DM, ...

Dapagliflozin for Chronic Kidney Disease - NCBI Bookshelf

The benefits of dapagliflozin in treating the dual epidemic of T2D with CV comorbidities have been recognized, and more recently, dapagliflozin has been ...

Effectiveness and Safety of Dapagliflozin for Black and White ...

Among Black and White patients with CKD, dapagliflozin was associated with reduced risks of progressive kidney disease (including kidney failure) ...

Efficacy and Safety of Dapagliflozin in Patients With CKD Across ...

Dapagliflozin reduced kidney and cardiovascular events and prolonged survival in patients with CKD, with and without type 2 diabetes, with no apparent effect ...

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose ...

Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney ...

A sizeable proportion of patients with chronic kidney disease (CKD) are reported to be frail. Here we examined the safety and efficacy of dapagliflozin in ...

Farxiga Phase III DAPA-CKD trial will be stopped early after ...

Farxiga is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 ...

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic ...

Dapagliflozin reduced the risk of kidney failure, death from cardiovascular causes or hospitalization for heart failure, and prolonged survival in people with ...

Dapagliflozin Utilization in Chronic Kidney Disease and Its Real ...

Claims data from the USA and Japan were used to describe patients with CKD and urinary albumin-to-creatinine ratio (UACR) < 200 mg/g who were ...

Dapa-CKD - ClinicalTrials.gov

Dapagliflozin in Patients With Heart Failure and Deterioration in ...

Although these therapies can be initiated even in patients with comorbid chronic kidney disease, some patients may face deterioration of kidney function over ...

a multicentre, randomised, active-controlled, phase 2b, clinical trial

In patients with chronic kidney disease, SGLT2 inhibitors and endothelin A receptor antagonists (ERAs) can reduce albuminuria and glomerular ...

Effects of Dapagliflozin in Patients With Kidney Disease, With and ...

Dapagliflozin reduced the risk of kidney failure, death from cardiovascular causes, or HF hospitalization, and prolonged survival in people with CKD, with or ...

Fluid homeostatic action of dapagliflozin in patients with chronic ...

Specifically, dapagliflozin ameliorated fluid retention and maintained euvolemic fluid status for 6 months in patients with CKD, regardless of ...

Chronic Kidney Disease | FARXIGA® (dapagliflozin) 5 mg & 10 mg ...

FARXIGA Significantly Reduced the Risk of Worsening Kidney Function or CV or Renal Death in Patients With CKD · FARXIGA Remains the Only SGLT2i Proven to ...